Novartis AG vs Petróleo Brasileiro SA — how do they compare? Novartis AG trades at $152.4 (market cap $295.37B), while Petróleo Brasileiro SA trades at $17.98 (market cap $112.19B). The key difference: Novartis AG is far larger — about 2.6× Petróleo Brasileiro SA's market cap, and Petróleo Brasileiro SA pays the higher dividend (9.42%). Which is the better fit depends on your goals.
| NVS | PBR | |
|---|---|---|
Market Cap | $295.37B | $112.19B |
Sector | Health | Technology |
52-Week High | $168.62 | $22.03 |
52-Week Low | $119.31 | $11.54 |
Enterprise Value | $336.69B | $172.61B |
Dividend Yield | 3.07% | 9.42% |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →